Over the 17‐day time course, we further treated tumours with vehicle control, MEK1‐low, or MEK1‐hi EVs via intratumoural injection on days 7, 12, and 15, in order to mimic the persistent release /presence of EVs from tumours (Figure 3a). This evidence concerns the gene MAP2K1 and neoplasm.